Peroxisome proliferator activated receptor agonists

US7345070B2 · kind B2 · utility

Assignee

• ELI LILLY AND COMPANY · US

Inventors

• Dawn Brooks · Indianapolis, US
• Alexander Godfrey · Greenwood, US
• Sarah Beth Jones · Greenwood, US
• James R. McCarthy · Dorpsstraat, US
• Christopher J. Rito · Mooresville, US
• Leonard Larry Winneroski, Jr. · Greenwood, US
• Yanping Xu · Noblesville, US

Key dates

• Filing date: Feb 9, 2005
• Grant date: Mar 18, 2008
• Expiry date: Oct 14, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.